Navigation Links
Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis
Date:11/9/2013

ATLANTA, GA Doctors at the North Shore-LIJ Health System on Saturday will present late-breaking data showing that an investigational drug Triferic is well tolerated and effective in treating iron deficiency in patients with chronic kidney disease undergoing dialysis. This data will be presented at the American Society of Nephrology's Kidney Week 2013 in Atlanta, GA.

Chronic kidney disease (CKD) is the slow loss of kidney function over time. The main function of the kidneys is to remove wastes and excess water from the body. When chronic kidney failure reaches an advanced stage, dangerous levels of fluid, electrolytes and wastes can accumulate in the body, and a patient will need to undergo hemodialysis (dialysis) a machine that filters wastes, salts and fluid from the blood. A common problem for patients on dialysis is iron deficiency. The body needs a certain amount of iron for overall good health and healthy blood cells, but excess iron gradually builds up in tissues and organs, eventually damaging them. Standard, current care for dialysis patients with iron deficiency is to intravenously inject 100 mg of iron into the bloodstream. But this method can result in oxidative stress and harm to people on dialysis.

Steven Fishbane, MD, and Azzour Hazzan, MD from the North Shore-LIJ Health System's Division of Nephrology in New York, in collaboration with Ajay Singh, MD, associate professor at Harvard Medical School, conducted two Phase 3 trials, CRUISE-1 and CRUISE-2, which demonstrated, in 300 patients in each trial, that Triferic administered at each dialysis treatment for up to 48 weeks effectively delivers iron and maintains the body's hemoglobin concentration constant. Triferic is a novel iron compound that has a unique mode of action in that it is delivered to the patient via their dialysis treatment as opposed to intravenous delivery. Triferic gradually delivers iron to the bone marrow and maintains hemoglobin without the rapid flux of iron caused by intravenous injection.

"Up until now, iron deficiency in chronic kidney disease patients who undergo dialysis has been treated almost exclusively with intravenous iron, which injects a large amount of iron directly into the blood stream. This can potentially be toxic for patients," said Dr. Fishbane. "Our study is important and should be of interest to patients because it shows Triferic is effective in preventing iron deficiency without inducing iron overload in patients. It more closely mimics the slower natural way of absorbing iron and with additional studies, we might be able to show it is an improved and preferred treatment option."


'/>"/>

Contact: Emily Eng
eng3@nshs.edu
516-562-2670
North Shore-Long Island Jewish (LIJ) Health System
Source:Eurekalert

Related medicine news :

1. Investigational agent targets gene signaling pathways to improve response for patients with CLL
2. Method patent issued for investigational new class of pain medication
3. Investigational malaria vaccine found safe and protective
4. Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
5. Investigational PARP inhibitor promising in BRCA-related cancers
6. NIH launches trial of investigational genital herpes vaccine
7. Investigational Drug Effective in Treating Iron Deficiency in Chronic Kidney Disease Patients on Dialysis: Study
8. HIV Prevention Pill Cost-Effective for High-Risk Men: Study
9. Pig stomach mucins are effective as anti-viral agents for consumer products
10. Lower-Dose Radioiodine Effective Against Thyroid Cancer
11. Aspirin as Effective as Warfarin for Heart Failure: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: